Interview with the President and CEO: BioVie Inc. (NASDAQ:BIVI)

Healthcare >> CEO Interviews >> November 12, 2023

Cuong Do is President and CEO of BioVie Inc. Prior to his appointment with BioVie, Mr. Do was President of Samsung Global Strategy Group where he helped to set the strategic direction for Samsung Group’s diverse business portfolio. He was previously the Chief Strategy Officer for Merck, a leading U.S. pharmaceuticals company. Mr. Do also held leadership roles in the technology space at Lenovo and Tyco Electronics, and was a senior partner at McKinsey & Company, where he spent 17 years helping to build the company’s healthcare, high tech and corporate finance practices. Mr. Do is an active entrepreneur who founded Callidus Biopharma (a biotech company working in rare diseases that was acquired by Amicus Therapeutics in 2013), Lysodel Therapeutics (a company developing an innovative pharmaceutical product for obesity), and M6P Therapeutics (a company developing gene and enzyme replacement therapies for rare lysosomal storage disorders). He holds a B.A. from Dartmouth College, and an MBA from the Tuck School of Business at Dartmouth. Profile

Word count: 3,132

TWST: Can you give us an overview or introduction to the company?

Mr. Do: BioVie is a small biotech startup that has two assets in clinical

Join for free to read a longer excerpt or purchase this article

Interview with the President and CEO: BioVie Inc. (NASDAQ:BIVI)

Top Company Interviews

CEO INTERVIEWS

SECTOR ROUNDTABLES

MONEY MANAGER INTERVIEWS

ANALYST INTERVIEWS

Interview with the President and CEO: BioVie Inc. (NASDAQ:BIVI)

Top Company Interviews

Register for a Free Account to gain greater access to The Wall Street Transcript right now

CEO INTERVIEWS

SECTOR ROUNDTABLES

MONEY MANAGER INTERVIEWS

ANALYST INTERVIEWS